75 results
424B5
LCTX
Lineage Cell Therapeutics Inc
22 Mar 24
Prospectus supplement for primary offering
4:32pm
to the spinal parenchyma in subacute and chronic SCI patients. Per the correspondence, the FDA advised that due to significant workload and conflicting … of a novel spinal cord delivery device in both subacute and chronic spinal cord injuries and continues to be evaluated in long-term follow-up from a Phase 1
8-K
EX-99.1
LCTX
Lineage Cell Therapeutics Inc
7 Mar 24
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:10pm
subacute and, for the first time, chronic spinal cord injury patients. Following the closing of our recent financing, a transaction conducted without … for the treatment of chronic and subacute spinal cord injury to enable initiation of DOSED (Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury
424B5
LCTX
Lineage Cell Therapeutics Inc
6 Feb 24
Prospectus supplement for primary offering
9:25am
spinal cord delivery device in both subacute and chronic SCI patients.
S-1
Our pipeline of allogeneic, or “off-the-shelf”, cell therapy programs
8-K
EX-99.1
bd1hn3cu
9 Nov 23
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.1
fgrqcxuf7a3c 5vcgg
12 Aug 21
LINEAGE REPORTs SECOND QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS ADDITIONAL PROGRESS FROM CLINICAL CELL THERAPY PROGRAMS
4:10pm
8-K
ng6cd 81cqe18
1 Mar 19
Other Events
12:00am
425
bby63lirhp837i
1 Mar 19
Business combination disclosure
12:00am
424B3
yv79z
4 Feb 19
Prospectus supplement
5:52pm
S-4/A
eldzja7oyimsgt
14 Jan 19
Registration of securities issued in business combination transactions (amended)
12:00am
S-4
9h3 5be0hpec3xu
4 Jan 19
Registration of securities issued in business combination transactions
5:05pm
8-K
EX-99.1
qac38 8gm
2 Aug 18
BioTime Reports Second Quarter Results and Recent Corporate Accomplishments
4:13pm